Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Endocyte ECYT

Healthcare Biotechnology
"Endocyte Inc is a biopharmaceutical company. It is engaged in developing targeted therapies for the treatment of cancer and inflammatory diseases."

Bullboard (NDAQ:ECYT)

View:
Post by David_Adellon Mar 22, 2015 5:18pm

Tip your toes on this one

Last earnings were good but  MM could take it lower to force out margin buyers.  Could  do a double bottom back to  5  before taking off!
208
Post by KETZAon May 07, 2014 1:12am

Worth the risk

There are bad days at the office -- and then there's what Endocyte (NASDAQ: EXYT) shareholders had to endure on Friday. The company announced that a phase 3 trial involving vintafolide, an ...more  
368
Post by Expatobserveron Apr 11, 2014 8:13pm

This SP goes down on a good news?

They had the good news that their cancer drug was approved by Europeans for sale in Europe. So SP goes down 7%. Go figure.
297
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

Dealroom for high-potential pre-IPO opportunities